Author/Editor | Twelves, Chris; Wong, Alfred; Nowacki, Marek P; Abt, Markus; Burris, Howard; Carrato, Alfredo; Cassidy, Jim; Cervantes, Andres; Fagerberg, Jan; Štabuc, Borut | |
Title | Capecitabine as adjuvant treatment for stage III colon cancer | |
Type | članek | |
Source | N Engl J Med | |
Vol. and No. | Letnik 352, št. 26 | |
Publication year | 2005 | |
Volume | str. 2696-704 | |
Language | eng | |
Abstract | Background. Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. Methods. We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. Results. Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20).Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). Conclusions Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer. | |
Descriptors | COLONIC NEOPLASMS ANTIMETABOLITES, ANTINEOPLASTIC CHEMOTHERAPY, ADJUVANT DEOXYCYTIDINE NEOPLASM STAGING AGE FACTORS SEX FACTORS DISEASE-FREE SURVIVAL SURVIVAL ANALYSIS MULTIVARIATE ANALYSIS |